<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; CRTX</title>
	<atom:link href="http://www.stockbloghub.com/tag/crtx/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Tue, 22 May 2012 18:53:06 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(CRTX) Cornerstone Therapeutics&#8217; Earnings Report Tops Consensus</title>
		<link>http://www.stockbloghub.com/2010/03/08/crtx-cornerstone-therapeutics-earnings-report-tops-consensus/30052</link>
		<comments>http://www.stockbloghub.com/2010/03/08/crtx-cornerstone-therapeutics-earnings-report-tops-consensus/30052#comments</comments>
		<pubDate>Tue, 09 Mar 2010 00:36:28 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Cornerstone Therapeutics Inc]]></category>
		<category><![CDATA[CRTX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=30052</guid>
		<description><![CDATA[Cornerstone Therapeutics Inc. (CRTX) reported fiscal fourth-quarter earnings of 20 cents per share (excluding special items), which was well above the Zacks Consensus Estimate of a loss of 4 cents. The company had earned 34 cents (excluding special items) in the year-ago quarter. The drop in quarterly earnings was attributable to higher operating costs and a tax provision. Quarterly Results Net revenue in the reported quarter was $30.8 million as against $20.8 million in the year-ago quarter, up approximately 48%. Sales of Curosurf, which is used to treat respiratory distress syndrome (RDS) in premature babies, came in at $8.3 million in the reported quarter. Cornerstone acquired the U.S. rights to Curosurf from Chiesi in the third quarter of 2009 and had begun to promote and sell the drug in Sept ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/08/crtx-cornerstone-therapeutics-earnings-report-tops-consensus/30052/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CRTX) Cornerstone Therapeutics Provides Guidance</title>
		<link>http://www.stockbloghub.com/2010/01/11/crtx-cornerstone-therapeutics-provides-guidance/24636</link>
		<comments>http://www.stockbloghub.com/2010/01/11/crtx-cornerstone-therapeutics-provides-guidance/24636#comments</comments>
		<pubDate>Mon, 11 Jan 2010 22:54:04 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Cornerstone Therapeutics Inc]]></category>
		<category><![CDATA[CRTX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24636</guid>
		<description><![CDATA[Recently, Cornerstone Therapeutics Inc. (CRTX) forecasted net revenues exceeding $112 million for the year ending December 31, 2010. The guidance for fiscal 2010 assumes that its branded products will contribute more than 75% of net revenues in 2010 compared to the 2009 contribution of 40%. The company expects to report net revenues greater than or equal to $104 million in fiscal 2009. Cornerstone expects to earn more than $10.2 million or 38 cents per share in 2010. Cornerstone Therapeutics Inc. is the merger product of the privately held Cornerstone BioPharma with the publicly traded Critical Therapeutics in 2008. The merger brought Zyflo CR ? the U.S. Food and Drug Administration (FDA) approved product for the prevention and chronic treatment of asthma in adults and children aged 12 and above ? ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/11/crtx-cornerstone-therapeutics-provides-guidance/24636/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CRTX) Cornerstone Therapeutics Tops Consensus Estimates</title>
		<link>http://www.stockbloghub.com/2009/11/11/crtx-cornerstone-therapeutics-tops-consensus-estimates/20298</link>
		<comments>http://www.stockbloghub.com/2009/11/11/crtx-cornerstone-therapeutics-tops-consensus-estimates/20298#comments</comments>
		<pubDate>Wed, 11 Nov 2009 20:31:29 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Cornerstone Therapeutics Inc]]></category>
		<category><![CDATA[CRTX]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20298</guid>
		<description><![CDATA[Cornerstone Therapeutics Inc. (CRTX) reported third-quarter earnings per share of 7 cents, compared to a profit of 49 cents in the year-ago quarter. The Zacks Consensus Estimate was pegged at 1 cent. Net revenues for the quarter were up 12.1% to $23.1 million as against $20.6 million in the year-ago quarter. Revenues were boosted by the acquisition of a few products during the quarter. Sales for two of the company’s products fell due to increased competition. Hyomax sales fell 39 %, to $7.6 million, while the AlleRx Dose Pack product line witnessed a 42 % decrease to $3.5 million. On the positive side, revenues from Spectracef sales increased $1.9 million for the reported quarter primarily due to the enhanced promotion of the drug by Cornerstone’s sales force to targeted physicians. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/11/crtx-cornerstone-therapeutics-tops-consensus-estimates/20298/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CRTX) Cornerstone Therapeutics Wins Factive Rights</title>
		<link>http://www.stockbloghub.com/2009/09/08/crtx-cornerstone-therapeutics-wins-factive-rights/14642</link>
		<comments>http://www.stockbloghub.com/2009/09/08/crtx-cornerstone-therapeutics-wins-factive-rights/14642#comments</comments>
		<pubDate>Wed, 09 Sep 2009 00:04:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Cornerstone Therapeutics Inc]]></category>
		<category><![CDATA[CRTX]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14642</guid>
		<description><![CDATA[Last week, Cornerstone Therapeutics Inc. (CRTX) announced the receipt of approval from the United States Bankruptcy Court for Massachusetts district regarding the acquisition of Factive&#8217;s (gemifloxacin mesylate) commercial rights  in North America and some European countries from Oscient Pharmaceuticals Corp., which filed for Chapter 11 bankruptcy protection in July. The transaction is worth $5 million in cash. Additionally, it includes an amount for purchased inventory, quarterly royalty payments based on adjusted net sales for a period of five years, and the assumption of certain liabilities. Factive, which belongs to the fluoroquinolone class of antibiotics, is indicated for the treatment of community-acquired pneumonia of mild to moderate severity and acute bacterial exacerbations of chronic bronchitis (ABECB).  It was launched in the U.S. in September 2004 and is the only fluoroquinolone approved in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/08/crtx-cornerstone-therapeutics-wins-factive-rights/14642/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

